

10/549958
JC17 Re PCT/PTO 15 SEP 2005
EXPRESS MAIL NO.: EV 531 712 866 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|------------------|--|----------------------|----------------|
| Application of: | Ensoli | Confirmation No.: | To Be Assigned |
| Application No.: | To Be Assigned (National Stage of PCT/EP02/04303, filed April 18, 2002) | Art Unit: | To Be Assigned |
| Filed: | On even date herewith | Examiner: | To Be Assigned |
| For: | USE OF INHIBITORS OF THE PROTEASE OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) TO BLOCK CELL MIGRATION AND/OR INVASION, TISSUE INFILTRATION AND OEDEMA FOR THE THERAPY OF DISEASES ASSOCIATED THEREWITH | Attorney Docket No.: | 11340-007-999 |

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicant respectfully direct the Examiner's attention to references A01, B01-B02 and C01-C05 listed on the attached revised PTO/SB/08 Form entitled "List of References Cited by Applicants." Pursuant to 37 C.F.R. § 1.98(a)(2)(i), copies of the cited U.S. patents and U.S. patent application publications (*i.e.*, reference A01) are not submitted herewith. A copy of references B01-B02 and C01-C05 is submitted herewith.

Identification of the listed references is not to be construed as an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the listed references and that the references be made of record in the file history of the application.

10/549958
JC17 Res PCT/PTO 15 SEP 2005

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, it is believed that no fee is due in connection herewith. However, should the Patent and Trademark Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: September 15, 2005


Adriane M. Antler 32,605
(Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

ATTY. DOCKET NO.

APPLICATION NO. 10/154,995
To Be Assigned
(National Stage of
PCT/EP02/04303, filed
April 18, 2002)

11340-007-999

APPLICANT

Ensoli

FILING DATE

On Even Date Herewith

GROUP

To Be Assigned

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|-----|-----------------|----------|--------------|-------|----------|----------------------------|
| | A01 | 6,506,555 | 01/14/03 | Andre et al. | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | YES | NO |
|--|-----|-----------------|----------|-----------------------------|-------|----------|-------------|-----|----|
| | B01 | WO 99/63998 | 12/16/99 | PCT (with English abstract) | | | | | |
| | B02 | WO 00/33654 | 06/15/00 | PCT | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|-----|--|
| | C01 | Andre et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13120-4. |
| | C02 | Berthelot et al. Dramatic cutaneous psoriasis improvement in a patient with the human immunodeficiency virus treated with 2',3'-dideoxy,3'-thiacytidine [correction of 2',3'-dideoxycytidine] and ritonavir. Arch Dermatol. 1997 Apr;133(4):531. |
| | C03 | Conant et al. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir. AIDS. 1997 Aug;11(10):1300-1. |
| | C04 | Sgadari et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002 Mar;8(3):225-32. |
| | C05 | International Search Report for International Application No. PCT/EP02/04303. |
| | | |
| | | |
| | | |

| EXAMINER | DATE CONSIDERED |
|----------|-----------------|
| | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.